Published in Eur J Clin Pharmacol on December 14, 2004
How to improve drug dosing for patients with renal impairment in primary care - a cluster-randomized controlled trial. BMC Fam Pract (2012) 0.93
e-SPC - delivering drug information in the 21st century: developing new approaches to deliver drug information to prescribers. Br J Clin Pharmacol (2012) 0.82
Clinical relevance of information in the Summaries of Product Characteristics for dose adjustment in renal impairment. Eur J Clin Pharmacol (2013) 0.82
Pro-active provision of drug information as a technique to address overdosing in intensive-care patients with renal insufficiency. Eur J Clin Pharmacol (2009) 0.78
Development of a standardized knowledge base to generate individualized medication plans automatically with drug administration recommendations. Br J Clin Pharmacol (2013) 0.77
Pilot study to test the feasibility of a trial design and complex intervention on PRIoritising MUltimedication in Multimorbidity in general practices (PRIMUMpilot). BMJ Open (2016) 0.77
Drug-Induced Nephrotoxicity and Dose Adjustment Recommendations: Agreement Among Four Drug Information Sources. Int J Environ Res Public Health (2015) 0.75
[Questionnaire surveying nephrologists on drug dose adjustment in patients with impaired kidney function]. Wien Klin Wochenschr (2010) 0.75
Definition of variables required for comprehensive description of drug dosage and clinical pharmacokinetics. Eur J Clin Pharmacol (2017) 0.75
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998) 32.05
Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA (1995) 26.38
Knowledge resource preferences of family physicians. J Fam Pract (1990) 5.31
Drug dosage in patients with renal failure optimized by immediate concurrent feedback. J Gen Intern Med (2001) 1.15
Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. Eur J Clin Pharmacol (2004) 0.94
Adverse drug effects in relation to renal function. Am J Med (1977) 0.94
Incorrect overdose management advice in the Physicians' Desk Reference. Ann Emerg Med (1997) 0.92
Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system. Ann Pharmacother (1993) 0.82
The product label: how pharmacokinetics and pharmacodynamics reach the prescriber. Clin Pharmacokinet (2002) 0.80
Drug labeling should be kept current. Clin Pharmacol Ther (2003) 0.77
Assessment and reporting of clinical pharmacology information in drug labeling. Clin Pharmacol Ther (2000) 0.75
Quality markers of drug information on the Internet: an evaluation of sites about St. John's wort. Am J Med (2002) 4.19
Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ (2006) 3.18
Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther (2005) 1.82
The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells. Nat Cell Biol (2010) 1.81
CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol (2008) 1.78
Factors influencing alert acceptance: a novel approach for predicting the success of clinical decision support. J Am Med Inform Assoc (2011) 1.66
Mail surveys: obsolescent model or valuable instrument in general practice research? Swiss Med Wkly (2005) 1.54
Pharmacokinetics of a netilmicin loading dose on the first postnatal day in preterm neonates with very low gestational age. Eur J Clin Pharmacol (2006) 1.51
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol (2009) 1.49
Multidisciplinary pain management based on a computerized clinical decision support system in cancer pain patients. Pain (2009) 1.48
Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother (2006) 1.47
In vitro assessment of methylene blue on chloroquine-sensitive and -resistant Plasmodium falciparum strains reveals synergistic action with artemisinins. Antimicrob Agents Chemother (2005) 1.46
Acute hyperhomocysteinemia decreases NO bioavailability in healthy adults. Atherosclerosis (2004) 1.44
Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther (2003) 1.39
Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malar J (2006) 1.37
Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol (2005) 1.32
Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther (2006) 1.30
Misspellings in drug information system queries: characteristics of drug name spelling errors and strategies for their prevention. Int J Med Inform (2010) 1.28
Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]. Malar J (2005) 1.28
Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother (2007) 1.27
High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol (2008) 1.27
Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol (2007) 1.26
Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit (2011) 1.24
"Quality of prenatal and maternal care: bridging the know-do gap" (QUALMAT study): an electronic clinical decision support system for rural Sub-Saharan Africa. BMC Med Inform Decis Mak (2013) 1.24
Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost (2005) 1.23
Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. Trop Med Int Health (2005) 1.23
Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharmacol (2004) 1.19
Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther (2004) 1.12
Hypoxia impairs systemic endothelial function in individuals prone to high-altitude pulmonary edema. Am J Respir Crit Care Med (2005) 1.09
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos (2006) 1.06
Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf (2010) 1.02
Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma. Rapid Commun Mass Spectrom (2007) 1.02
Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol (2012) 1.02
Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother (2010) 1.00
Efavirenz treatment and false-positive results in benzodiazepine screening tests. Clin Infect Dis (2009) 1.00
Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol Pharmacol (2004) 0.99
Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther (2004) 0.98
Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol (2003) 0.97
Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. Eur J Clin Pharmacol (2004) 0.94
Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.94
Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.94
Induction of multiple drug transporters by efavirenz. J Pharmacol Sci (2009) 0.93
How to improve drug dosing for patients with renal impairment in primary care - a cluster-randomized controlled trial. BMC Fam Pract (2012) 0.93
7-Aminoactinomycin D for apoptosis staining in flow cytometry. Anal Biochem (2012) 0.93
Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. Br J Clin Pharmacol (2004) 0.92
Oral contraception does not alter single dose saquinavir pharmacokinetics in women. Br J Clin Pharmacol (2004) 0.92
Quality of drug information on the World Wide Web and strategies to improve pages with poor information quality. An intervention study on pages about sildenafil. Br J Clin Pharmacol (2004) 0.92
EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur Respir J (2013) 0.91
On the alert: future priorities for alerts in clinical decision support for computerized physician order entry identified from a European workshop. BMC Med Inform Decis Mak (2013) 0.90
Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circ Heart Fail (2011) 0.90
A prospective three-step intervention study to prevent medication errors in drug handling in paediatric care. J Clin Nurs (2014) 0.89
Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther (2003) 0.89
Pharmacologic abrogation of the mitotic spindle checkpoint by an indolocarbazole discovered by cellular screening efficiently kills cancer cells. Cancer Res (2009) 0.89
Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system. Intensive Care Med (2010) 0.88
Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL. Br J Clin Pharmacol (2002) 0.88
Modulation of endothelial and smooth muscle function by bed rest and hypoenergetic, low-fat nutrition. J Appl Physiol (1985) (2005) 0.87
Automatic detection of adverse events to predict drug label changes using text and data mining techniques. Pharmacoepidemiol Drug Saf (2013) 0.87
Autosomal-dominant hypertension with type E brachydactyly is caused by rearrangement on the short arm of chromosome 12. Hypertension (2004) 0.87
Rule-based standardised switching of drugs at the interface between primary and tertiary care. Eur J Clin Pharmacol (2007) 0.86
Inequalities in out-of-pocket payments for health care services among elderly Germans--results of a population-based cross-sectional study. Int J Equity Health (2014) 0.86
Endothelial venodilator response in carriers of genetic polymorphisms involved in NO synthesis and degradation. Br J Clin Pharmacol (2004) 0.86
Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. Int J Pharm (2010) 0.86
Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1'-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry. Anal Bioanal Chem (2012) 0.86
Highly sensitive determination of saquinavir in biological samples using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.85
Opportunities to reduce medication regimen complexity: a retrospective analysis of patients discharged from a university hospital in Germany. Drug Saf (2013) 0.85
Substantial reduction of inappropriate tablet splitting with computerised decision support: a prospective intervention study assessing potential benefit and harm. BMC Med Inform Decis Mak (2009) 0.85
Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur J Pharmacol (2007) 0.85
Prioritising the prevention of medication handling errors. Pharm World Sci (2008) 0.83
Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. Clin Pharmacokinet (2004) 0.83
Coded entry versus free-text and alert overrides: what you get depends on how you ask. Int J Med Inform (2010) 0.83
In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem Pharmacol (2004) 0.83
Prescribing errors in patients with documented drug allergies: comparison of ICD-10 coding and written patient notes. Pharm World Sci (2009) 0.83
Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol (2011) 0.83
Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies. Pharmacotherapy (2010) 0.82
e-SPC - delivering drug information in the 21st century: developing new approaches to deliver drug information to prescribers. Br J Clin Pharmacol (2012) 0.82
Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein. Pharmacology (2009) 0.82
The A14-scale: development and evaluation of a questionnaire for assessment of adherence and individual barriers. Pharm World Sci (2009) 0.82
A drug database model as a central element for computer-supported dose adjustment within a CPOE system. J Am Med Inform Assoc (2004) 0.82
Management of potential drug interactions in community pharmacies: a questionnaire-based survey in Switzerland. Eur J Clin Pharmacol (2007) 0.82
Assessment of levothyroxine sodium bioavailability: recommendations for an improved methodology based on the pooled analysis of eight identically designed trials with 396 drug exposures. Clin Pharmacokinet (2004) 0.81
CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores. Br J Clin Pharmacol (2014) 0.81
Development and evaluation of a computerised clinical decision support system for switching drugs at the interface between primary and tertiary care. BMC Med Inform Decis Mak (2012) 0.81
Undeclared exposure to St. John's Wort in hospitalized patients. Br J Clin Pharmacol (2004) 0.80
A systematic review of medication administration errors with transdermal patches. Expert Opin Drug Saf (2014) 0.80
Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1'-hydroxylation in vitro. Drug Metab Dispos (2012) 0.80
Drug dose adjustments in patients with renal impairment. Am J Kidney Dis (2009) 0.80
Quantification of retinoid concentrations in human serum and brain tumor tissues. Anal Chim Acta (2012) 0.80
Appropriateness of timing of drug administration in electronic prescriptions. Pharm World Sci (2010) 0.79
Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochem Pharmacol (2004) 0.79
Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug. Br J Clin Pharmacol (2003) 0.79
NKIM-6, a new immortalized human brain capillary endothelial cell line with conserved endothelial characteristics. Cell Tissue Res (2006) 0.79